Astellas Pharma revenue decreased from ¥1.3 trillion in 2019 to ¥1.3 trillion in 2020, a (0.4%) decrease.

Annual Revenue (¥)

Astellas Pharma revenue was ¥1.3 t in FY, 2020 which is a (0.4%) year over year decrease from the previous period.

FY, 2018FY, 2019FY, 2020
Revenue¥1.3 t¥1.31 t¥1.3 t

Annual Growth Rate (%)

Revenue Breakdown

Business Segment

Geographic Segment

Astellas Pharma revenue breakdown by business segment: 30.7% from XTANDI, 14.8% from Prograf, 12.4% from Betanis/Myrbetriq/BETMIGA and 42.0% from Other

Astellas Pharma revenue breakdown by geographic segment: 34.4% from United States , 28.8% from Japan and 36.7% from Other

FY, 2020FY, 2019FY, 2018
XTANDI¥399.99 b¥33.31 b¥294.3 b
Prograf¥192.93 b¥195.71 b¥198.47 b
Betanis/Myrbetriq/BETMIGA ¥161.56 b¥147.18 b¥125.75 b
Vesicare¥44.72 b¥94.97 b¥102.31 b
Other¥501.64 b¥535.44 b¥579.49 b
FY, 2020FY, 2019FY, 2018
Americas ¥459.65 b¥435.11 b
EMEA¥357.01 b¥351.28 b
Japan¥375.17 b¥376.16 b¥406.41 b
Asia and Oceania$113.53 b$107.51 b
United States ¥448.08 b
Other¥477.59 b

Need Data?

Craft can deliver 250+ data points of financial, operating, and human capital indicators on companies via API.

Footer menu